Chest Mobility, Cough Strength, Muscle Strength, Physical Activity and Quality of Life in Parkinson’s Patients with post-COVID-19

Chest Mobility, Cough Strength, Muscle Strength, Physical Activity and Quality of Life in Parkinson’s Patients who have had COVID-19

Status

Not yet recruiting

Phases

Unknown

Study type

Observational

Source

ANZCTR

Registry ID

ACTRN12623000564651

Enrollment

Registered

2023-05-25

Start date

2023-06-05

Completion date

Unknown

Last updated

2023-06-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

Acute worsening and long-term sequelae of motor and non-motor symptoms have also been described in Parkinson's patients during and after SARS-CoV-2 infection, also known as prolonged COVID. The effects on pain, chest mobility, cough strength, muscle strength, physical activity levels and quality of life in Parkinson's patients with COVID-19 are still unclear today. For this reason, in our study, we aim to comparatively investigate pain, chest mobility, cough strength, muscle strength, physical activity levels and quality of life in Parkinson's patients with COVID-19 and without COVID-19 and to show the relationships between these outcome measures.

Interventions

In this research, the data of Parkinson's patients who have had and have not had COVID-19 will be collected face to face. Chest mobility, cough strength, muscle strength, physical activity and quality of life will be evaluated in all Parkinson's patients. The data to be obtained through all these evaluations will be collected from at one time and in a time lasting maximum of about 1 hour. Step count tracking with pedometer will be done for 3 days for each individual.

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

Inclusion criteria for Parkinson's patients with COVID-19; • Being diagnosed with COVID-19 at least 12 weeks ago and recovered, • Being over 18 years old, • Volunteering to participate in the research, • Being diagnosed with Parkinson's disease • Comorbid conditions (such as hypertension, diabetes) are under control • Being able to perceive assessments (Standardized Mini Mental Test score of 24 and above) • Having the ability to ambulate and walk independently • Being in stage 1 - 4 according to the Modified Hoehn-Yahr Scale Inclusion criteria for Parkinson's patients without COVID-19; • Not being diagnosed or suspected of COVID-19 • Being over 18 years old, • Volunteering to participate in the research, • Being diagnosed with Parkinson's disease • Having comorbid conditions (such as hypertension, diabetes) which are under control • Being able to perceive assessments (Standardized Mini Mental Test score of 24 and above) • Having the ability to ambulate and walk independently • Being in stage 1 - 4 according to the Modified Hoehn-Yahr Scale

Exclusion criteria

Exclusion criteria for Parkinson's patients with and without COVID-19; • Sudden drug or dose change during the study period • A history of any acute/chronic orthopedic, cardiovascular, pulmonary, psychiatric or neuromuscular disease that may prevent measurements from being made. • Having had myocardial infarction and pulmonary embolism in the last 30 days, • Having a history of additional neurological (stroke, head trauma, peripheral nerve diseases, brain and spinal cord tumors, etc.) diseases other than Parkinson's disease • Having severe vision loss or vestibular dysfunction • Patients with blood pressure values above 140/90 and below 90/50 in blood pressure measurements made before the study, with arrhythmia on ECG, with a history of shortness of breath and/or palpitation

Outcome results